Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475899 | 0.91 | RAF1 (0.58) | ALDH1A1CCR2MAPTRAF1L3MBTL1 | |
| SCHEMBL5477276 | 0.90 | MCHR1 (0.54) | ALDH1A1MAPTRECQLPOLBSCN9A | |
| SCHEMBL5484126 | 0.87 | ALDH1A1 (0.57) | ALDH1A1CCR2MAPTRECQLPOLB | |
| SCHEMBL5483156 | 0.86 | SCN9A (0.59) | ALDH1A1MAPTRECQLPOLBSCN9A | |
| SCHEMBL5480122 | 0.84 | MCHR1 (0.58) | MAPTRECQLPOLBSCN9ARAF1 | |
| SCHEMBL14430677 | 0.82 | CHRM4 (0.62) | ALDH1A1MAPTRECQLPOLBNAMPT | |
| SCHEMBL14430801 | 0.81 | EPHX2 (0.61) | ALDH1A1MAPTRECQLPOLBNAMPT | |
| SCHEMBL5474268 | 0.81 | MCHR1 (0.56) | POLBSCN9ARAF1L3MBTL1LMNA | |
| SCHEMBL5481939 | 0.81 | TSHR (0.66) | ALDH1A1MAPTRECQLPOLBNAMPT | |
| SCHEMBL5474324 | 0.81 | POLB (0.75) | ALDH1A1MAPTRECQLPOLBCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | ALDH1A1 172/4885CCR2 1696/4885MAPT 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.